ViroPharma Inc. (VPHM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
730 STOCKTON DRIVE, EXTON, PA 19341
6104587300

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

N/A

Data derived from most recent annual or quarterly report
Market Cap 3.296 Billion Shares Outstanding65.97 Million Avg 30-day Volume 865.926 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.91
Price to Revenue6.5445 Debt to Equity0.2314 EBITDA-37.505 Million
Price to Book Value3.8698 Operating Margin-19.881 Enterprise Value2.71 Billion
Current Ratio5.389 EPS Growth-2.237 Quick Ratio3.668
1 Yr BETA 0.6988 52-week High/Low 0.0 / Profit Margin-14.6827
Operating Cash Flow Growth-110.8221 Altman Z-Score5.0254 Free Cash Flow to Firm -43.773 Million
View SEC Filings from VPHM instead.

View recent insider trading info

Funds Holding VPHM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VPHM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DOUGHERTY MICHAEL R

  • Director
0 2014-01-24 0

BROOKE PAUL A

  • Director
0 2014-01-24 0

PIEN HOWARD H

  • Director
0 2014-01-24 0

MILANO VINCENT PRESIDENT AND CEO

  • Officer
  • Director
0 2014-01-24 0

DOYLE THOMAS F VP STRATEGIC INITIATIVES

  • Officer
0 2014-01-24 0

GLASER ROBERT

  • Director
0 2014-01-24 0

CLAYPOOL WILLIAM D MD

  • Director
0 2014-01-24 0

BROOM COLIN MD VP & CHIEF SCIENTIFIC OFFICER

  • Officer
0 2014-01-24 0

LEONE JOHN R

  • Director
0 2014-01-24 0

SOLAND DANIEL B VP, CHIEF OPERATING OFFICER

  • Officer
0 2014-01-24 0

ROWLAND CHARLES A JR VP, CHIEF FINANCIAL OFFICER

  • Officer
0 2014-01-24 0

PIETRUSKO ROBERT VP, REGULATORY & QUALITY

  • Officer
0 2014-01-24 0

WOLF JOHN PETER III VP, GENERAL COUNSEL

  • Officer
0 2014-01-24 0

MCHUGH JULIE

  • Director
0 2014-01-24 0

FLETCHER ROBERT C. V.P., BUSINESS DEVELOPMENT

  • Officer
0 2014-01-24 0

KIRBY JOHN J. V.P., CHIEF ACCOUNTING OFFICER

  • Officer
0 2014-01-24 0

MORRIS RICHARD STEVEN CHIEF ACCOUNTING OFFICER

  • Officer
0 2012-06-04 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
1,966,090 2011-12-14 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
9,840,469 2011-12-14 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
303,264 2011-12-14 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
4,751 2011-05-10 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
1,306 2011-05-10 0

BALDINO FRANK JR

  • Director
0 2010-02-22 0

DE ROSEN MICHEL

  • Director
137,100 2008-11-07 0

BAKER BIOTECH CAPITAL II (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
1,957,127 2006-02-27 0

BAKER BIOTECH CAPITAL II (Z) (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
103,540 2006-02-27 0

BAKER BIOTECH CAPITAL III (Z) (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
122,122 2006-02-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments